CRISPR base editing technology is a promising genome editing tool as (i) it does not require a DNA template to introduce mutations and (ii) it avoids creating DNA double-strand breaks, which can lead to unintended chromosomal alterations or elicit an unwanted DNA damage response. Given many cancers originate from point mutations in cancer-driving genes, the application of base editing for either modelling tumour development, therapeutic editing, or functional screening is of great promise. In this review, we summarise current DNA base editing technologies and will discuss recent advancements and existing hurdles for its usage in cancer research.
CITATION STYLE
Pal, M., & Herold, M. J. (2021, February 1). CRISPR base editing applications for identifying cancer-driving mutations. Biochemical Society Transactions. Portland Press Ltd. https://doi.org/10.1042/BST20200550
Mendeley helps you to discover research relevant for your work.